Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by canadapieton Sep 17, 2019 11:02am

106 Views

Post# 30135298

right price/ no BO

Well, with all the latest info regarding the market size and penetration rate, it is obvious the price won't do much and don't deserve to be higher now!
Our "hope" (again) is for the third possibility = NASH/NAFLD !
But that is still a ways off and it seems that Big Pharma is not intrested in a niche player, nor in the product for such a small patient population!

Be sure B P is looking very closely to choose what they might buy! The University of Ghent had immediately GILD on the phone when they read what that team find out in the HIV space.